<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201219049763N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-06-08</date_registration>
      <primary_sponsor>Iranian academic center for education culture and research</primary_sponsor>
      <public_title>Assessing the effectiveness of topical peppermint cream and orally ingestible peppermint oxymel mouthwash on halitosis and vomiting of breast cancer patients during chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>A clinical trial to assess the effectiveness of antiemetic and anti-halitosis topical peppermint cream and orally ingestible peppermint oxymel mouthwash in breast cancer patients during chemotherapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>225</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53233</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization is done by assigning the subjects under study to 6 blocks. In each block, individuals are randomly assigned to one of the groups using topical peppermint, peppermint oral mouthwash, and control in a ratio of 2-2-2. The order of random assignment of individuals to the study groups in each block is kept in sealed envelopes, and the individual who has nothing to do with measuring the outcomes is responsible for assigning individuals to different treatments, Blinding description: Due to the difference in the combination of the two drugs used, it is not possible to blind the participant and clinical care. Also, in order to follow the patients and evaluate the effectiveness and side effects of the drug, it is necessary to emphasize the adherence to the drug, so the evaluator cannot be blind. In this case, it is only possible to blind the researcher and analyst.</study_design>
      <phase>3</phase>
      <hc_freetext>Breast cancer patients treated with chemotherapy drugs.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group one: In addition to taking the anti-nausea and antiemetic drugs Aprepitant and Dexamethasone, patients use mint serpentine mouthwash.Its ingredients are 5% water, 5% honey and 1% grape vinegar, to which 2% peppermint extract is added. How to use: 3 times a day, on days 1 to 6 of each course of chemotherapy. Each time, 2 tablespoons (equivalent to 10 ml) of mouthwash mixed with 6 tablespoons of water are mixed in the mouth and then swallowed. Intervention 2: Patients use topical peppermint cream in addition to the anti-nausea and antiemetic drugs Aprepitant and Dexamethasone.The ratio of its components is Cetostearyl alcohol 8g, Cetomacrogol 2g, poly ethylen glycol 6g , propylen glycol 6g, ethanol 10g, distilled water 60cc, peppermint essential oil 1cc. How to use: 3 times a day, on days 1 to 6 of each course of chemotherapy. Each time, rub 1 cm on the forehead and 0.5 cm on the back of each ear. Intervention 3: Control group: Patients taking only the usual anti-nausea and vomiting medications Aprepitant and Dexamethasone.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza Madjid Ansari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 146 , South Gandhi Ave , Gandhi Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1517964311</zip>
        <telephone>+98 21 8879 6208</telephone>
        <email>majidansari@acecr.ac.ir</email>
        <affiliation>Iranian academic center for education culture and research</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Madjid Ansari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 146 , South Gandhi Ave , Gandhi Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1517964311</zip>
        <telephone>+98 21 8879 6208</telephone>
        <email>majidansari@acecr.ac.ir</email>
        <affiliation>Iranian academic center for education culture and research</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>No history of nausea and vomiting for other reasons
Full consciousness
Literacy
Complete satisfaction in participating in this project
Breast cancer, ac4T4 chemotherapy regimen, taking anti-nausea and vomiting drugs Aprepitant and Dexamethasone
No history of allergies Medicinal plants
No history of respiratory diseases, asthma, diabetes and autoimmune diseases</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Eliminate patients who use medications or treatments other than those prescribed during the study to reduce nausea and vomiting
Patients who forget to use the product and mouthwash three or more times in a row</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group one: In addition to taking the anti-nausea and antiemetic drugs Aprepitant and Dexamethasone, patients use mint serpentine mouthwash.Its ingredients are 5% water, 5% honey and 1% grape vinegar, to which 2% peppermint extract is added. How to use: 3 times a day, on days 1 to 6 of each course of chemotherapy. Each time, 2 tablespoons (equivalent to 10 ml) of mouthwash mixed with 6 tablespoons of water are mixed in the mouth and then swallowed.</i_keyword>
      <i_keyword>Patients use topical peppermint cream in addition to the anti-nausea and antiemetic drugs Aprepitant and Dexamethasone.The ratio of its components is Cetostearyl alcohol 8g, Cetomacrogol 2g, poly ethylen glycol 6g , propylen glycol 6g, ethanol 10g, distilled water 60cc, peppermint essential oil 1cc. How to use: 3 times a day, on days 1 to 6 of each course of chemotherapy. Each time, rub 1 cm on the forehead and 0.5 cm on the back of each ear.</i_keyword>
      <i_keyword>Control group: Patients taking only the usual anti-nausea and vomiting medications Aprepitant and Dexamethasone.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea score in questionnaires. Timepoint: At the beginning of the study, every day based on the Daily questionnaire, every 14 days based on the Rhodes questionnaire. Method of measurement: Daily questionnaire and  Rhodes questionnaire.</prim_outcome>
      <prim_outcome>Halitosis scores on questionnaires. Timepoint: At the beginning of the study, every day based on the Daily questionnaire, every 14 days based on the Rhodes questionnaire. Method of measurement: Daily questionnaire and  Rhodes questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iranian academic center for education culture and research</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-13</approval_date>
        <contact_name>Motamed Cancer Institute</contact_name>
        <contact_address>Gandhi South Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
